6-Fluoroprednisolone | 62358-13-8

• 英文名称: 6-Fluoroprednisolone
• 英文别名: (8S,9S,10R,11S,13S,14S,17R)-6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
• CAS: 62358-13-8
• 化学式: C₂₁H₂₇FO₅
• 分子量: 378.4
• InChiKey: MYYIMZRZXIQBGI-ZHAFKKQJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  94.8
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• CORTICOID-17,21-DICARBOXYLIC ESTERS AND CORTICOSTEROID 17-CARBOXYLIC ESTER 21-CARBONIC ESTERS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS
  申请人：——

  公开号：US20020103392A1

  公开（公告）日：2002-08-01

  Corticoid 17,21-dicarboxylic esters and corticosteroid 17-carboxylic ester 21-carbonic esters, processes for their preparation and pharmaceuticals containing these compounds Corticoid 17,21-dicarboxylic esters and corticoid 17-carboxylic ester 21-carbonic esters of the formula I 1 are described, in which A is CHOH and CHCl, CH 2 , C═O or 9(11) double bond; Y is H, F or Cl; Z is H, F or methyl; R(1) is aryl or hetaryl; R(2) is alkyl and R(3) is H or methyl. They are obtained, inter alia, by reacting a compound of the formula II, 2 in which R(5) is OH, with an activated carboxylic acid of the formula III, R(6)—CO—(O) n [(C 1 -C 4 )-alkyl] m -R(1)   III. They have a very strong local and topical antiinflammatory action and exhibit a very good ratio of local to systemic antiinflammatory effects. They are used, inter alia, as agents for treating inflammatory dermatoses.

  糖皮质激素17,21-二羧酸酯和糖皮质激素17-羧酸酯21-羧酸酯的制备方法和含有这些化合物的药物被描述。其中化学式I1中，A为CHOH和CHCl，CH2，C═O或9(11)双键；Y为H，F或Cl；Z为H，F或甲基；R(1)为芳基或杂环基；R(2)为烷基，R(3)为H或甲基。它们可以通过将化学式II中R(5)为OH的化合物与化学式III中的活化羧酸反应而获得。它们具有非常强的局部和局部抗炎作用，并表现出很好的局部和全身抗炎效应比。它们被用于治疗炎症性皮肤病等。
• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Wortmannin conjugates and uses thereof
  申请人：Yuan Hushan

  公开号：US20090324489A1

  公开（公告）日：2009-12-31

  The invention features conjugates of wortmannin, and wortmannin derivatives, and their use as inhibitors of PI3-kinase activity in treating cancer, inflammatory diseases, and C. albicans infections.

  本发明涉及沃特曼宁及其衍生物的共轭物，并将其用作PI3-激酶活性抑制剂，用于治疗癌症、炎症性疾病和C. albicans感染。
• 6-Alpha-fluoro-16-methyl-prednisolone-17,21 diesters and pharmaceutical compositions containing them
  申请人：STEROSYNT Ltd.

  公开号：EP0029924A1

  公开（公告）日：1981-06-10

  Novel 6α-fluoro-, 6a-fluoro-16a-methyl- and 6a-fluoro-16β-methyl-prednisolone 17,21-diesters, and a method for their preparation, are described. The novel products are particularly valuable as anti-inflammatory agents.

  本文描述了新型 6α-氟-、6a-氟-16a-甲基-和 6a-氟-16β-甲基-泼尼松龙 17,21 二酯及其制备方法。这些新产品作为抗炎剂特别有价值。
• Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases
  申请人：Combinatorx, Incorporated

  公开号：EP2070550A1

  公开（公告）日：2009-06-17

  The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more additional agents.

  本发明的特点是通过向患者单独或与一种或多种附加制剂联合使用四取代嘧啶嘧啶，治疗被诊断患有或有可能患上免疫炎症性疾病的患者。本发明的另一个特点是含有四取代嘧啶嘧啶的组合物与一种或多种附加制剂的组合物。